NCT05581550

Somatostatin Receptor Imaging in NPC, EBV Related Cancers

Somatostatin Receptor Imaging in Nasopharyngeal Cancer, Epstein-Barr Virus (EBV) Related Cancers and Other Rare Tumors

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: National Cancer Centre, Singapore · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.

Conditions

• Nasopharyngeal Cancer
• Epstein-Barr Virus Related Carcinoma

Interventions

Type	Name	Description
RADIATION	FDG-PET	Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose. Scanning will be performed at an interval of at least 60 minutes following the injection.
RADIATION	Galium-68 DOTATATE	200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.

Timeline

• Start date: 2020-06-29
• Primary completion: 2025-07-17
• Completion: 2025-07-17
• First posted: 2022-10-14
• Last updated: 2025-07-20

Locations

1 site across 1 country: Singapore